|
The impact of neoadjuvant chemotherapy (NAC) ± anti-HER2 antibodies (mAbs) on gut microbiome composition in early breast cancer (EBC): A pilot prospective study. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
Karolina Kazmierczak-Siedlecka |
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; MSD Oology; Pfizer; Roche/Genentech |
Consulting or Advisory Role - GlaxoSmithKline |
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Pfizer |
| |
|
|
| |
|
Consulting or Advisory Role - BMS; MSD Oncology; Roche |
Speakers' Bureau - AstraZeneca; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - Takeda |